Meningioma is the primary central nervous system tumour with the highest recorded prevalence. Research on meningiomas has shown an association with hormone receptor expression, but the underlying pathophysiologic mechanisms remain unclear. This systematic review presents the available information on the role of progesterone and estrogen in meningioma’s pathogenesis, prognosis, and treatment. The study used the Preferred Reporting Items for Systemic Review and MetaAnalysis (PRISMA) 2020 guidelines. The authors searched and downloaded relevant published articles from the following databases; PubMed, PubMed Central (PMC), MEDLINE, the Cochrane Library, and Google Scholar. The downloaded articles were screened using set eligibility criteria and appropriate quality appraisal tools and subsequently relevant data was extracted using standardized questionnaires. Based on the papers reviewed, progesterone receptor expression in meningioma is associated with significantly more favourable prognostic factors and treatment outcomes while a negative correlation exists between overall survival and the presence of estrogen receptors. In conclusion, analysing hormone receptor expression in meningioma appears necessary for targeted hormonal and endocrine therapy. A suitable reference population must also be defined in future extensive prospective multi-centre and multi-national clinical studies